Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Peptide injections at Formation are administered by Jeff Atlas, PA-C, a licensed physician assistant who brings years of experience from his previous role in orthopaedics, giving patients the benefit of hands-on musculoskeletal expertise in every session
Clinical trials have shown no evidence of increased calcitonin levels (which have been measured in all clinical trials of GLP-1 receptor agonists) or MTC rates with GLP-1 receptor agonist use
When combined with semaglutide, both peptides titrate simultaneously but on different schedules
Safety: what we know, what we dont What clinical trial safety reviews suggest The clinical safety review literature reports several reassuring signals: No meaningful increase in IGF-1 in monitored long-term studies (jofem.org) No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org) No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org) The major limitation: long-term real-world certainty is thin The problem with many peptides is not that everything is dangerousits that the certainty level is often lower than patients assume
It is sold under standard medical-supply rules
CagriSema in its anticipated commercial form will likely also come as a pre-filled pen
